Biotechnology: A Revolution for Medicine?
By Kara Miller
This week, we look at medical treatments and devices that may change how diseases are diagnosed and treated.
Just about a decade ago, when the human genome was sequenced, many scientists believed that a new world of biologically-based medicines were on their way.
But today we face two huge problems. Big diseases, like cancer and Alzheimer's, feel intractable. And health care costs continue to skyrocket.
We’ll look at biotechnology and whether it has the potential to revolutionize medicine’s cost and effectiveness.
David Lucchino, CEO of Semprus BioSciences
David Steinmiller, COO, OPKO Diagnostics
Michael J. Cima, professor of Materials Science and Engineering at MIT
What's Next for Biotech
A biotechnology venture capitalist — and one of the first investors in Genzyme — joins us to talk about the most exciting therapies in the pipeline and what he’s investing in now.
Comment on This Article
About Innovation HubEach week, Kara Miller talks to Boston's most innovative thinkers, examining new ideas and potential solutions to today’s many challenges. Topics range from education to health care to green energy. Join us on Saturdays at 7 a.m. and Sundays at 10 p.m.
As a radio host, Kara Miller has interviewed thinkers from E.J. Dionne to Howard Gardner, Deepak Chopra to Lani Guinier. She is a panelist on WGBH-TV's "Beat the Press," as well as an Assistant Professor at the University of Massachusetts Dartmouth. Her writing has appeared in The Boston Globe, The National Journal, The Boston Herald, Boston Magazine, and The International Herald Tribune.
News updates from WGBH